Compare CBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | GKOS |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | 3036 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | CBC | GKOS |
|---|---|---|
| Price | $28.47 | $125.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $28.67 | ★ $126.92 |
| AVG Volume (30 Days) | 545.7K | ★ 1.1M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $12.15 | $23.32 |
| Revenue Next Year | $6.34 | $27.43 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $22.50 | $73.16 |
| 52 Week High | $29.07 | $148.11 |
| Indicator | CBC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 51.74 |
| Support Level | $23.28 | $99.82 |
| Resistance Level | $29.07 | $130.23 |
| Average True Range (ATR) | 0.73 | 8.73 |
| MACD | -0.09 | -0.97 |
| Stochastic Oscillator | 75.71 | 51.09 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.